Literature DB >> 3121517

Inactivation of HIV in plasma derivatives by beta-propiolactone and UV irradiation.

H Dichtelmüller1, W Stephan, A M Prince, L Gürtler, F Deinhardt.   

Abstract

The inactivation of HIV in human plasma and plasma derivatives by combined treatment with beta-propiolactone and UV-irradiation was investigated. beta-propiolactone inactivated greater than or equal to 3.5 log10 and UV greater than or equal to 2.8 log10 HIV in plasma and beta-propiolactone greater than or equal to 3.5 log10 in cryoprecipitate and UV irradiation greater than or equal to 4.5 log10 in factor VIII concentrate.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3121517     DOI： 10.1007/bf01647745

Source DB:  PubMed          Journal:  Infection        ISSN： 0300-8126            Impact factor:   3.553


  10 in total

1.  Asymptomatic liver disease in haemophiliacs.

Authors:  P M Mannucci; A Capitanio; E Del Ninno; M Colombo; F Pareti; Z M Ruggeri
Journal:  J Clin Pathol       Date:  1975-08       Impact factor: 3.411

2.  [LAV/HTLV-III antibodies in blood and blood products].

Authors:  L Gürtler; J Eberle; F Deinhardt
Journal:  Dtsch Med Wochenschr       Date:  1985-10-25       Impact factor: 0.628

3.  Hepatitis-free and stable human serum for intravenous therapy.

Authors:  W Stephan
Journal:  Vox Sang       Date:  1971-05       Impact factor: 2.144

4.  Undegraded human immunoglobulin for intravenous use.

Authors:  W Stephan
Journal:  Vox Sang       Date:  1975       Impact factor: 2.144

5.  Inactivation of lymphadenopathy associated virus by chemical disinfectants.

Authors:  B Spire; F Barré-Sinoussi; L Montagnier; J C Chermann
Journal:  Lancet       Date:  1984-10-20       Impact factor: 79.321

6.  Inactivation of hepatitis A virus added to pooled human plasma by beta-propiolactone treatment and ultraviolet irradiation.

Authors:  G G Frösner; W Stephan; H Dichtelmüller
Journal:  Eur J Clin Microbiol       Date:  1983-08       Impact factor: 3.267

7.  beta-propiolactone/ultraviolet irradiation: a review of its effectiveness for inactivation of viruses in blood derivatives.

Authors:  A M Prince; W Stephan; B Brotman
Journal:  Rev Infect Dis       Date:  1983 Jan-Feb

8.  Quantitative assays for evaluation of HTLV-III inactivation procedures: tri(N-butyl)phosphate:sodium cholate and beta-propiolactone.

Authors:  A M Prince; B Horowitz; H Dichtelmueller; W Stephan; R C Gallo
Journal:  Cancer Res       Date:  1985-09       Impact factor: 12.701

9.  Antibodies to human T cell leukaemia virus-associated membrane antigens in haemophiliacs: evidence for infection before 1980.

Authors:  B L Evatt; S F Stein; D P Francis; D N Lawrence; M F McLane; J S McDougal; T H Lee; T J Spira; C Cabradilla; J I Mullens; M Essex
Journal:  Lancet       Date:  1983-09-24       Impact factor: 79.321

10.  Inactivation of the Hutchinson strain of non-A, non-B hepatitis virus by combined use of beta-propiolactone and ultraviolet irradiation.

Authors:  A M Prince; W Stephan; H Dichtelmüller; B Brotman; T Huima
Journal:  J Med Virol       Date:  1985-06       Impact factor: 2.327
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.